Durability of glycemic control using U-500 insulin

Alexandria M. Dailey, Jennifer A. Gibert, Lisa R. Tannock

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Previous short-term studies evaluating U-500 insulin have reported improvements in glycemic control but with significant weight gain. This study was performed to examine the glycemic durability of U-500 insulin in highly insulin resistant subjects, and to determine if weight gain was continuous with use. Patients using U-500 insulin provided consent for chart reviews for up to 3 years prior to and 3 years after use of U-500 insulin. Charts were reviewed for physical and metabolic data from 53 subjects using U-500 insulin of which 20 used U-500 insulin for 3 years. Use of U-500 insulin led to an approximate 1% decrease in HbA1c within 3-6 months of use which was sustained for up to 3 years. Patients required increased insulin doses (by ∼80%) over the first 6-12 months with a corresponding weight gain (∼10. lbs) and a spike in hypoglycemia symptoms, but then insulin doses and body weight, as well as glycemic control and hypoglycemic symptoms, stabilized over subsequent follow up. Use of U-500 insulin in a clinical diabetes practice leads to sustained improvements in glycemic control following a period of insulin titration and weight gain. Despite the weight gain, glycemic control was sustained for up to 3 years.

Original languageEnglish (US)
Pages (from-to)340-344
Number of pages5
JournalDiabetes Research and Clinical Practice
Volume95
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Insulin
Weight Gain
Hypoglycemia
Hypoglycemic Agents
Body Weight

Keywords

  • HbA1c
  • Hypoglycemia
  • Insulin resistance
  • Weight gain

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Durability of glycemic control using U-500 insulin. / Dailey, Alexandria M.; Gibert, Jennifer A.; Tannock, Lisa R.

In: Diabetes Research and Clinical Practice, Vol. 95, No. 3, 01.03.2012, p. 340-344.

Research output: Contribution to journalArticle

Dailey, Alexandria M. ; Gibert, Jennifer A. ; Tannock, Lisa R. / Durability of glycemic control using U-500 insulin. In: Diabetes Research and Clinical Practice. 2012 ; Vol. 95, No. 3. pp. 340-344.
@article{f495d2a6a61f41a8b19c54be24a20c6e,
title = "Durability of glycemic control using U-500 insulin",
abstract = "Previous short-term studies evaluating U-500 insulin have reported improvements in glycemic control but with significant weight gain. This study was performed to examine the glycemic durability of U-500 insulin in highly insulin resistant subjects, and to determine if weight gain was continuous with use. Patients using U-500 insulin provided consent for chart reviews for up to 3 years prior to and 3 years after use of U-500 insulin. Charts were reviewed for physical and metabolic data from 53 subjects using U-500 insulin of which 20 used U-500 insulin for 3 years. Use of U-500 insulin led to an approximate 1{\%} decrease in HbA1c within 3-6 months of use which was sustained for up to 3 years. Patients required increased insulin doses (by ∼80{\%}) over the first 6-12 months with a corresponding weight gain (∼10. lbs) and a spike in hypoglycemia symptoms, but then insulin doses and body weight, as well as glycemic control and hypoglycemic symptoms, stabilized over subsequent follow up. Use of U-500 insulin in a clinical diabetes practice leads to sustained improvements in glycemic control following a period of insulin titration and weight gain. Despite the weight gain, glycemic control was sustained for up to 3 years.",
keywords = "HbA1c, Hypoglycemia, Insulin resistance, Weight gain",
author = "Dailey, {Alexandria M.} and Gibert, {Jennifer A.} and Tannock, {Lisa R.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1016/j.diabres.2011.10.030",
language = "English (US)",
volume = "95",
pages = "340--344",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Durability of glycemic control using U-500 insulin

AU - Dailey, Alexandria M.

AU - Gibert, Jennifer A.

AU - Tannock, Lisa R.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Previous short-term studies evaluating U-500 insulin have reported improvements in glycemic control but with significant weight gain. This study was performed to examine the glycemic durability of U-500 insulin in highly insulin resistant subjects, and to determine if weight gain was continuous with use. Patients using U-500 insulin provided consent for chart reviews for up to 3 years prior to and 3 years after use of U-500 insulin. Charts were reviewed for physical and metabolic data from 53 subjects using U-500 insulin of which 20 used U-500 insulin for 3 years. Use of U-500 insulin led to an approximate 1% decrease in HbA1c within 3-6 months of use which was sustained for up to 3 years. Patients required increased insulin doses (by ∼80%) over the first 6-12 months with a corresponding weight gain (∼10. lbs) and a spike in hypoglycemia symptoms, but then insulin doses and body weight, as well as glycemic control and hypoglycemic symptoms, stabilized over subsequent follow up. Use of U-500 insulin in a clinical diabetes practice leads to sustained improvements in glycemic control following a period of insulin titration and weight gain. Despite the weight gain, glycemic control was sustained for up to 3 years.

AB - Previous short-term studies evaluating U-500 insulin have reported improvements in glycemic control but with significant weight gain. This study was performed to examine the glycemic durability of U-500 insulin in highly insulin resistant subjects, and to determine if weight gain was continuous with use. Patients using U-500 insulin provided consent for chart reviews for up to 3 years prior to and 3 years after use of U-500 insulin. Charts were reviewed for physical and metabolic data from 53 subjects using U-500 insulin of which 20 used U-500 insulin for 3 years. Use of U-500 insulin led to an approximate 1% decrease in HbA1c within 3-6 months of use which was sustained for up to 3 years. Patients required increased insulin doses (by ∼80%) over the first 6-12 months with a corresponding weight gain (∼10. lbs) and a spike in hypoglycemia symptoms, but then insulin doses and body weight, as well as glycemic control and hypoglycemic symptoms, stabilized over subsequent follow up. Use of U-500 insulin in a clinical diabetes practice leads to sustained improvements in glycemic control following a period of insulin titration and weight gain. Despite the weight gain, glycemic control was sustained for up to 3 years.

KW - HbA1c

KW - Hypoglycemia

KW - Insulin resistance

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=84857237437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857237437&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2011.10.030

DO - 10.1016/j.diabres.2011.10.030

M3 - Article

C2 - 22088791

AN - SCOPUS:84857237437

VL - 95

SP - 340

EP - 344

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -